Acute Agitation and Aggression Treatment Market Report 2026

The acute agitation and aggression treatment market size has grown strongly in recent years. It will grow from $6.05 billion in 2025 to $6.36 billion in 2026 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to increasing prevalence of psychiatric disorders, rising emergency department visits for agitation, wider availability of antipsychotic medications, expansion of mental health services, growing awareness of behavioral health conditions.

The acute agitation and aggression treatment market size is expected to see strong growth in the next few years. It will grow to $8.37 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to growing demand for fast-acting therapeutic options, increasing investments in neuropsychiatric drug development, rising use of digital mental health tools, expansion of integrated behavioral care models, stronger focus on patient-centric treatment pathways. Major trends in the forecast period include increasing adoption of rapid-acting pharmacologic treatments, rising focus on personalized psychiatry approaches, growing integration of digital monitoring tools, expansion of emergency behavioral care protocols, enhanced emphasis on patient safety.

The rising incidence of dementia is expected to drive the growth of the acute agitation and aggression treatment market in the coming years. Dementia refers to conditions marked by impaired memory, cognition, and the ability to perform everyday tasks. A common symptom in dementia patients is agitation, which can manifest as restlessness, repetitive behaviors, or frequent hand movements. Treatments for acute agitation and aggression play a critical role in managing these symptoms, reducing risks, improving patient quality of life, and addressing underlying causes. For example, in February 2023, the Australian Institute of Health and Welfare reported that approximately 401,300 Australians had dementia in 2022, and this number is projected to rise to 849,300 by 2058. Consequently, the growing prevalence of dementia is supporting expansion in the acute agitation and aggression treatment market.

Key companies in this market are focusing on developing innovative products to meet patient needs, such as generic versions of existing drugs. Generic Zyprexa, for instance, contains the active ingredient olanzapine and is used to treat psychotic conditions. In September 2023, Camber Pharmaceuticals, a US-based pharmaceutical company, launched a generic version of Zyprexa, an atypical antipsychotic indicated for managing acute agitation associated with schizophrenia and bipolar I mania.

In April 2023, SK Capital Partners LP, a US-based private investment firm, acquired Apotex Inc. for an undisclosed amount. This acquisition enables SK Capital to expand its presence in the generic pharmaceutical market and increase its investment in the healthcare sector. Apotex Inc., based in Canada, is a producer of generic pharmaceuticals, including drugs for the treatment of acute agitation and aggression.

Major companies operating in the acute agitation and aggression treatment market are Pfizer Inc., Johnson and Johnson Pvt Ltd., F Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Mylan NV, Biogen Inc., Bausch Health Companies Inc., UCB SA, Servier Laboratories, Sun Pharmaceutical Industries Ltd., AstraZeneca PLC, Ono Pharmaceutical Co Ltd., Apotex Inc., H Lundbeck A/S, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Neurocrine Biosciences Inc., Aurobindo Pharma Limited, Alkermes plc., Indivior plc., Sunovion Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., and Alexza Pharmaceuticals Inc.

North America was the largest region in the acute agitation and aggression treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute agitation and aggression treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute agitation and aggression treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the acute agitation and aggression treatment market by increasing costs of imported active pharmaceutical ingredients, injectable formulations, medical devices, and packaging materials. Hospitals and psychiatric facilities in North America and Europe are most affected due to reliance on global pharmaceutical supply chains, while Asia-Pacific faces cost pressure on drug manufacturing inputs. These tariffs are raising treatment costs and affecting drug availability timelines. However, they are also encouraging domestic pharmaceutical production, local sourcing of raw materials, and increased investment in regional drug manufacturing capabilities.

The acute agitation and aggression treatment market research report is one of a series of new reports that provides acute agitation and aggression treatment market statistics, including acute agitation and aggression treatment industry global market size, regional shares, competitors with a acute agitation and aggression treatment market share, detailed acute agitation and aggression treatment market segments, market trends and opportunities, and any further data you may need to thrive in the acute agitation and aggression treatment industry. This acute agitation and aggression treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acute agitation and aggression treatment refers to medical and therapeutic interventions aimed at managing and reducing the sudden onset of restlessness, irritability, and hostile behavior in patients. These symptoms can arise from a variety of underlying conditions, including psychiatric disorders, neurological disorders, or substance use and withdrawal effects.

The primary types of acute agitation and aggression treatments include behavioral approaches, environmental interventions, and pharmacologic approaches. The behavioral approach focuses on the scientific study of observable behavior and its environmental determinants. Pharmacologic treatments include drugs such as antipsychotics, benzodiazepines, and others, administered via routes such as oral or intramuscular delivery. These treatments are applied across various indications, including schizophrenia, dementia, bipolar disorder, depression, drug-induced agitation and aggression, and alcohol withdrawal. They are utilized by multiple end users, including hospitals, ambulatory surgical centers, psychiatric care facilities, and other healthcare settings.

The acute agitation and aggression treatment market includes revenues earned by entities by providing treatment with de-escalation techniques, psychosocial support, and medical evaluation. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute agitation and aggression treatment market also consists of sales of lorazepam, chlorpromazine, and quetiapine API, droperidol, olanzapine, and ziprasidone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.